Synthetic membrane-receiver complexes
Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.
1. An enucleated erythroid cell comprising at least 1,000 copies of an intracellular exogenous polypeptide comprising phenylalanine ammonia lyase (PAL),
wherein the enucleated erythroid cell is made by a process comprising introducing an exogenous nucleic acid encoding the exogenous polypeptide into a nucleated erythroid cell precursor.
2. The enucleated erythroid cell of claim 1 , which comprises at least 10,000 copies of the exogenous polypeptide.
3. The enucleated erythroid cell of claim 1 , wherein the exogenous polypeptide consists essentially of PAL.
4. The enucleated erythroid cell of claim 1 , wherein the exogenous polypeptide consists of PAL.
5. The enucleated erythroid cell of claim 1 , wherein the exogenous nucleic acid comprises DNA.
6. The enucleated erythroid cell of claim 1 , wherein the exogenous nucleic acid comprises RNA.
7. The enucleated erythroid cell of claim 1 , which is a reticulocyte.
8. The enucleated erythroid cell of claim 1 , which is a mature erythrocyte.
9. The enucleated erythroid cell of claim 1 , which lacks A and B antigens.
10. The enucleated erythroid cell of claim 1 , wherein the nucleated erythroid cell precursor is a CD34+ hematopoietic stem cell.
11. The enucleated erythroid cell of claim 1 , which is a human cell.
12. A pharmaceutical composition comprising a plurality of the enucleated erythroid cells of claim 1 .
13. The pharmaceutical composition of claim 12 , wherein at least about 90% of enucleated erythroid cells in the pharmaceutical composition comprise the exogenous polypeptide.
14. The pharmaceutical composition of claim 12 , wherein at least 70% of the cells in the pharmaceutical composition are the enucleated erythroid cells of claim 1 .
15. An enucleated erythroid cell comprising at least 1,000 copies of an intracellular exogenous polypeptide comprising phenylalanine ammonia lyase (PAL),
wherein the exogenous polypeptide is not fused to an endogenous polypeptide, and
wherein the enucleated erythroid cell is made by a process comprising introducing into a nucleated erythroid cell precursor an exogenous nucleic acid encoding the exogenous polypeptide.
16. The enucleated erythroid cell of claim 15 , which comprises at least 10,000 copies of the exogenous polypeptide.
17. The enucleated erythroid cell of claim 15 , wherein the exogenous polypeptide consists essentially of PAL.
18. The enucleated erythroid cell of claim 15 , wherein the exogenous polypeptide consists of PAL.
19. The enucleated erythroid cell of claim 15 , wherein the exogenous nucleic acid comprises DNA.
20. The enucleated erythroid cell of claim 15 , wherein the exogenous nucleic acid comprises RNA.
21. The enucleated erythroid cell of claim 15 , which is a reticulocyte.
22. The enucleated erythroid cell of claim 15 , which is a mature erythrocyte.
23. The enucleated erythroid cell of claim 15 , which lacks A and B antigens.
24. The enucleated erythroid cell of claim 1 , wherein the exogenous polypeptide is not fused to an endogenous polypeptide.
25. The enucleated erythroid cell of claim 15 , wherein the nucleated erythroid cell precursor is a CD34+ hematopoietic stem cell.
26. The enucleated erythroid cell of claim 15 , which is a human cell.
27. A pharmaceutical composition comprising a plurality of the enucleated erythroid cells of claim 15 .
28. The pharmaceutical composition of claim 27 , wherein at least about 90% of enucleated erythroid cells in the pharmaceutical composition comprise the exogenous polypeptide.
29. The pharmaceutical composition of claim 27 , wherein at least 70% of the cells in the pharmaceutical composition are the enucleated erythroid cells of claim 1 .